Virax Biolabs Group Ltd
VRAX0.510USD
-0.032-5.90%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
2.21MMarktkapitalisierung
--KGV TTM
mehr Informationen über Virax Biolabs Group Ltd Unternehmen
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Virax Biolabs Group Ltd Informationen
BörsenkürzelVRAX
Name des UnternehmensVirax Biolabs Group Ltd
IPO-datumJul 14, 2022
CEOMr. James Foster
Anzahl der mitarbeiter19
WertpapierartOrdinary Share
GeschäftsjahresendeJul 14
AddresseBiocity Glasgow
StadtLONDON
BörseNASDAQ Capital Market Consolidated
LandUnited Kingdom
PostleitzahlML1 5UH
Telefon4402077887414
Websitehttps://www.viraxbiolabs.com
BörsenkürzelVRAX
IPO-datumJul 14, 2022
CEOMr. James Foster
Führungskräfte von Virax Biolabs Group Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Oct 17
Aktualisiert: Fri, Oct 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Foster (James)
6.63%
Armistice Capital LLC
5.25%
Citadel Advisors LLC
0.69%
Mccracken (Nigel Ph.D.)
0.54%
Norton (Evan)
0.35%
Andere
86.53%
Aktionäre
Aktionäre
Anteil
Foster (James)
6.63%
Armistice Capital LLC
5.25%
Citadel Advisors LLC
0.69%
Mccracken (Nigel Ph.D.)
0.54%
Norton (Evan)
0.35%
Andere
86.53%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
8.23%
Hedge Fund
5.95%
Bank and Trust
0.12%
Andere
85.71%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
22
263.22K
6.06%
-53.31K
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
2023Q3
24
636.78K
40.92%
-179.86K
2023Q2
22
639.17K
41.06%
-174.53K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Foster (James)
368.57K
8.49%
+80.58K
+27.98%
Mar 31, 2025
Armistice Capital LLC
228.04K
5.25%
+228.04K
--
Sep 30, 2024
Citadel Advisors LLC
30.16K
0.69%
+16.62K
+122.73%
Jun 30, 2025
Mccracken (Nigel Ph.D.)
23.33K
0.54%
+23.33K
--
Mar 31, 2025
Norton (Evan)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
National Bank of Canada
5.00K
0.12%
+5.00K
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Datum
Art
Verhältnis
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
